Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

ML-3000 fails to meet all efficacy endpoints in E.U. trial

Feb. 21, 2002

AGIX-4207 completes phase I in rheumatoid arthritis

Feb. 21, 2002

Combinations of PDE3 and PDE4 inhibitors for autoimmune diseases available from NIH

Feb. 20, 2002

IL-13 gene therapy improves the course of arthritis in rats

Feb. 20, 2002

Selective inhibitors of COX-2 synthesized at Merck Frosst

Feb. 19, 2002

Abbott claims phenylsulfanyl derivatives for inflammation, etc.

Feb. 19, 2002

NO-flurbiprofen more effective and safer than flurbiprofen in accelerating tendon healing

Feb. 18, 2002

New licensing agreement signed by JT for JTE-522

Feb. 15, 2002

Negative response obtained from Health Canada for Pennsaid Topical Solution

Feb. 11, 2002

Potent and selective PDE7 inhibitors discovered at Celltech

Feb. 6, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...